Define one clinical question: who should be tested, what result is actionable, which decision changes, how quickly it must return, and what happens when the result is negative, uncertain, or unexpected. Review professional guidelines, FDA labeling and authorization, payer policy, local expertise, and the population actually served. A panel's technical breadth is not proof of clinical usefulness.

Rank use cases by evidence, unmet need, test performance, actionability, patient volume, turnaround requirement, workforce capacity, coverage, and equity risk. Examples may include an FDA-authorized companion diagnostic tied to an oncology therapy or a guideline-supported inherited-condition pathway. CDC's Tier 1 public-health genomics work has highlighted hereditary breast and ovarian cancer syndrome, Lynch syndrome, and familial hypercholesterolemia as conditions with evidence-based applications, although the exact clinical pathway and current guideline must still be verified.

Do not confuse research with care. NIH's All of Us Research Program demonstrates the scientific potential of linked genomic and health data, but a research association is not automatically ready for a clinical order set. Require a formal evidence review and version date before deploying a test or rule. Define who monitors new labels, guideline revisions, variant reclassification, and withdrawn evidence.

Set nonadoption criteria. If the result does not change a decision, the laboratory cannot meet quality or turnaround needs, counseling is unavailable, or patients cannot access the recommended intervention, postpone the program.

A scanned PDF in the chart is not personalized care. Use structured data where feasible and make the authoritative report available to the patient and care team. Build ordering criteria, specimen tracking, prior authorization, result routing, clinical decision support, consultation, treatment, referral, and follow-up as one pathway.

Design for every result category. A pathogenic finding may trigger therapy, surveillance, or family-risk discussion; a negative result may not eliminate clinical risk; a variant of uncertain significance generally should not be treated as a definitive answer. The responsible specialist and current guideline should determine action. Decision support should cite its evidence version, show who owns the next step, and avoid interruptive alerts when a quieter workflow will work.

For companion diagnostics, verify that the test and therapeutic product relationship matches current FDA information and that specimen, disease, and labeling requirements are met. For Medicare beneficiaries, CMS's national coverage determination for next-generation sequencing applies to defined somatic and germline cancer circumstances; coverage outside those circumstances can depend on Medicare Administrative Contractors and other payer policies. Confirm current patient-specific coverage before representing a test as covered.

Close the loop. Track order to collection, laboratory receipt, result, clinician acknowledgement, patient communication, recommended action, and completion. Create escalation for critical delays, failed specimens, unreviewed results, and patients who cannot access the indicated specialist or treatment.